Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eczema drug shows promise in early trial

NCT ID NCT06248814

Symptom relief Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new medicine called BMS-986326 in 64 adults with moderate-to-severe atopic dermatitis (eczema) who did not get enough relief from creams or needed stronger treatments. The main goal was to check the drug's safety and how the body processes it. Researchers also looked at whether the drug could reduce eczema severity and affect certain immune cells.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

64 people

The number who actually took part.

Started

Mar 2024

Finished

Nov 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Must have diagnosis of atopic dermatitis (AD) at least 12 months prior to screening * Documented history of inadequate response to treatment with topical medication for at least 4 weeks, unless topical treatments are otherwise medically inadvisable, or has required systemic therapy for control of disease * All the following must be present to confirm moderate-to-severe AD * Eczema Area and Severity Index score ≥ 12 (at Screening and Day 1) * Body Surface Area ≥ 10% (at Screening and Day 1) * Validated Investigator Global Assessment for Atopic Dermatitis ≥ 3 (at Screening and Day 1) * Peak Pruritus Numerical Rating Scale ≥ 4 (at Screening) Exclusion Criteria: * Evidence of an active and/or concurrent inflammatory skin condition that would interfere with the Investigator or subject-driven evaluations of AD * Any major surgery within the last 30 days before the first dose of study intervention, or any surgery planned during the course of the study * Any other sound medical, psychiatric, and/or social reason as determined by the investigator Other protocol-defined inclusion/exclusion criteria apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dermatitis, atopic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema dermatitis Eczema skin disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dermatitis, atopic

Contacts and locations

Locations

  • Local Institution - 0001

    Rzeszów, Podkarpackie Voivodeship, 35-055, Poland

  • Local Institution - 0002

    Córdoba, X, 14004, Spain

  • Local Institution - 0004

    Prague, PR, 100 00, Czechia

  • Local Institution - 0005

    Chemnitz, Saxony, 09117, Germany

  • Local Institution - 0006

    Clermont-Ferrand, 63003, France

  • Local Institution - 0008

    Pierre-Bénite, 69495, France

  • Local Institution - 0009

    Pardubice, 530 02, Czechia

  • Local Institution - 0010

    Nice, 06200, France

  • Local Institution - 0011

    Berlin, State of Berlin, 10117, Germany

  • Local Institution - 0012

    Lübeck, Schleswig-Holstein, 23562, Germany

  • Local Institution - 0013

    Las Palmas de Gran Canaria, GC, 35010, Spain

  • Local Institution - 0015

    Krakow, Lesser Poland Voivodeship, 30-149, Poland

  • Local Institution - 0016

    Katowice, Silesian Voivodeship, 40-081, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.